Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians

CONCLUSIONS: Variation exists among CF physicians in their preferred choice of primary antibiotic and use of dornase alfa. These preferences are driven by professional opinion, possibly reflecting a lack of evidence to base policy recommendations. Evidence from high-quality clinical trials is needed to inform physician decision making.PMID:34266854 | DOI:10.1136/bmjresp-2021-000956

Source: Respiratory Care - July 16, 2021 Category: Respiratory Medicine Authors: Grace Currie Anna Tai Tom Snelling Andr é Schultz Source Type: research